The new artificial intelligence-based software and robot-assisted biopsy technology helps providers catch and treat lung cancer in its earliest stages.

Noon, Chief Executive Officer of Inspira, commented “We are positioning the Company to expand into a high-growth diagnostics market through the planned acquisition of a development-ready liquid biopsy ...

All-share acquisition positions Inspira to expand into a multi-billion dollar diagnostics market with a development-ready innovative technology; transaction structured to include significant ...

Tal Parnes, Chairman of the Board of Inspira Technologies, stated: “The contemplated acquisition of this liquid biopsy platform represents a significant value inflection point for Inspira, adding a ...

Investing.com -- Inspira Technologies OXY B.H.N. Ltd (NASDAQ:IINN) stock gained 5.1% in Thursday premarket trading after the company outlined its strategic framework for expanding into liquid biopsy ...

PRNewswire/ -- (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today provided preliminary unaudited ...

KNOXVILLE, TN, UNITED STATES, January 8, 2026 /EINPresswire.com/ -- Daisy Genomics Inc. (“Daisy Genomics”) and New Day ...

Official websites use .mil A .mil website belongs to an official U.S. Department of Defense organization in the United States ...

Koelis, SAS ("Koelis" or the "Company", a leader and innovator in MRI-ultrasound fusion guidance for prostate cancer interventions, recently announced that the Centers for Medicare & Medicaid ...

Northwestern Medicine and Tempus AI, Inc. (NASDAQ: TEM) are collaborating to expand access to genomic testing for ...

LifeNet Health is advancing organ recovery through its innovative application of Specialist Direct’s (SDI) Mobile ...

Inspira Technologies Oxy BHN ( ($IINN) ) has issued an announcement. On January 5, 2026, Inspira Technologies Oxy B.H.N. Ltd. signed a non-binding ...